209 related articles for article (PubMed ID: 34135307)
21. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
22. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
Kansara R
Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
[TBL] [Abstract][Full Text] [Related]
23. The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis.
Lin Z; Chen X; Liu L; Zeng H; Li Z; Xu B
Crit Rev Oncol Hematol; 2022 Aug; 176():103756. PubMed ID: 35809794
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis.
Jeong H; Cho H; Kim H; Chae H; Lee JB; Lee K; Kim S; Lee SW; Ryu JS; Kim KW; Chae EJ; Huh J; Park CS; Yoon DH; Suh C
Blood Adv; 2021 Apr; 5(8):2142-2152. PubMed ID: 33881464
[TBL] [Abstract][Full Text] [Related]
25. [Risk assessment and prophylactic treatment strategies for central nervous system relapse of diffuse large B-cell lymphoma].
Miyazaki K
Rinsho Ketsueki; 2023; 64(6):490-496. PubMed ID: 37407473
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma.
Ghose A; Kundu R; Latif T
Crit Rev Oncol Hematol; 2014 Sep; 91(3):292-303. PubMed ID: 24698003
[TBL] [Abstract][Full Text] [Related]
27. Model for Predicting Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Discussion of Prophylaxis Measures.
Cui JY; Liu YF; Gao B; Mi L; Deng LJ; Zhu J; Hou SL
World Neurosurg; 2023 Nov; 179():e387-e396. PubMed ID: 37652134
[TBL] [Abstract][Full Text] [Related]
28. Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma.
Bernard S; Hachon L; Diasonama JF; Madaoui C; Aguinaga L; Miekoutima E; Moatti H; Perrial E; Madelaine I; Brice P; Thieblemont C
Ann Hematol; 2021 Apr; 100(4):979-986. PubMed ID: 33608849
[TBL] [Abstract][Full Text] [Related]
29. Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.
Goldschmidt N; Horowitz NA; Heffes V; Darawshy F; Mashiach T; Shaulov A; Gatt ME; Dann EJ
Leuk Lymphoma; 2019 Aug; 60(8):1890-1898. PubMed ID: 30689468
[TBL] [Abstract][Full Text] [Related]
30. Pilot trial of systemic methotrexate plus R-CHOP regimen with intrathecal methotrexate for simultaneous central nervous system and systemic diffuse large B cell lymphoma.
Yoo KH; Lee JY; Lim SH; Ko YH; Kim SJ; Kim WS
Acta Haematol; 2015; 133(2):179-82. PubMed ID: 25323539
[TBL] [Abstract][Full Text] [Related]
31. Central nervous system relapse in patients with diffuse large B cell lymphoma: analysis of the risk factors and proposal of a new prognostic model.
Kanemasa Y; Shimoyama T; Sasaki Y; Tamura M; Sawada T; Omuro Y; Hishima T; Maeda Y
Ann Hematol; 2016 Oct; 95(10):1661-9. PubMed ID: 27370993
[TBL] [Abstract][Full Text] [Related]
32. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL.
Savage KJ; Slack GW; Mottok A; Sehn LH; Villa D; Kansara R; Kridel R; Steidl C; Ennishi D; Tan KL; Ben-Neriah S; Johnson NA; Connors JM; Farinha P; Scott DW; Gascoyne RD
Blood; 2016 May; 127(18):2182-8. PubMed ID: 26834242
[TBL] [Abstract][Full Text] [Related]
33. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP
Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484
[TBL] [Abstract][Full Text] [Related]
34. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.
Arkenau HT; Chong G; Cunningham D; Watkins D; Agarwal R; Sirohi B; Trumper M; Norman A; Wotherspoon A; Horwich A
Ann Oncol; 2007 Mar; 18(3):541-5. PubMed ID: 17164228
[TBL] [Abstract][Full Text] [Related]
35. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.
Villa D; Connors JM; Shenkier TN; Gascoyne RD; Sehn LH; Savage KJ
Ann Oncol; 2010 May; 21(5):1046-52. PubMed ID: 19861575
[TBL] [Abstract][Full Text] [Related]
36. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.
González-Barca E; Canales M; Salar A; Ferreiro-Martínez JJ; Ferrer-Bordes S; García-Marco JA; Sánchez-Blanco JJ; García-Frade J; Peñalver J; Bello-López JL; Sancho JM; Caballero D;
Ann Hematol; 2016 May; 95(6):893-9. PubMed ID: 27025508
[TBL] [Abstract][Full Text] [Related]
37. Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis.
Fang Y; Su N; Ma S; Cai J; Zhong L; Li W; Huang H; Li Z; Huang H; Xia Y; Liu P; Guo L; Li Z; Wu Y; Tian X; Wang J; Zhang Y; Cai Q
Ann Hematol; 2022 Mar; 101(3):595-605. PubMed ID: 34985557
[TBL] [Abstract][Full Text] [Related]
38. Rituximab plus a CHOP-like regimen, central nervous system prophylaxis, and contralateral testicular irradiation for localized primary testicular diffuse large B-cell lymphoma lead to prolonged progression-free survival.
Ichikawa K; Noguchi M; Koike M; Aritaka N; Sekiguchi Y; Sunami Y; Tsutsui M; Hosone M; Hirano T; Gotoh A; Komatsu N
Int J Hematol; 2014 Oct; 100(4):370-8. PubMed ID: 25085255
[TBL] [Abstract][Full Text] [Related]
39. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.
El-Galaly TC; Villa D; Michaelsen TY; Hutchings M; Mikhaeel NG; Savage KJ; Sehn LH; Barrington S; Hansen JW; Smith D; Rady K; Mylam KJ; Larsen TS; Holmberg S; Juul MB; Cordua S; Clausen MR; Jensen KB; Johnsen HE; Seymour JF; Connors JM; de Nully Brown P; Bøgsted M; Cheah CY
Eur J Cancer; 2017 Apr; 75():195-203. PubMed ID: 28237865
[TBL] [Abstract][Full Text] [Related]
40. Central nervous system involvement in diffuse large B-cell lymphoma.
Yamamoto W; Tomita N; Watanabe R; Hattori Y; Nakajima Y; Hyo R; Hashimoto C; Motomura S; Ishigatsubo Y
Eur J Haematol; 2010 Jul; 85(1):6-10. PubMed ID: 20236301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
